ReviewEnvironmental science. Processes & impacts2022
To be or not to be degraded: in defense of persistence assessment of chemicals.
Review in Environmental science. Processes & impacts, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Confidently Uncertain: Probabilistic Machine Learning to Predict Soil Biotransformation Half-Lives.Environmental science & technology · 2026Article
- "The Dose Makes the Poison": Relevance of Paracelsus's Principle for Modern Chemical Hazard Assessment with New Approach Methodologies.Environmental science & technology · 2026Article
- Uncovering the role of chemical pollutants in shaping biological invasions.Proceedings. Biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterizing the degradation behavior of chemicals in the environment is a key component of chemical hazard and risk assessment. Persistence has been successfully characterized for readily and for slowly degradable chemicals using standardized tests, but for the third group of chemicals with intermediate degradability ("middle group"), the assessment is less straightforward. Whether chemicals of this group behave as persistent or not in a given environment depends on environmental factors such as the presence of sorbents that can limit the bioavailability of chemicals. Uncertainties associated with current persistence assessments of chemicals in the middle group do not imply that persistence assessment is generally inconsistent, too ambiguous for regulatory use, and not useful in chemical hazard and risk assessment. Given the complexity of the environmental factors influencing chemical degradation, and the diversity of commercial chemicals, it has to be accepted though that for chemicals in the middle group even improved testing methods will not remove all of the immanent heterogeneity in their persistence data. For cases with widely different but technically valid persistence data, a weight-of-evidence approach is necessary and the "benefit of the doubt" should follow the precautionary principle in order to protect human and ecosystem health. We maintain that technically valid persistence data, although they might be considered dissatisfying from a scientific point of view because of high variability or even inconclusiveness, can well be sufficient for regulatory purposes. As with anything, also in persistence assessment, the scientific logic aims for a mechanistic description of the processes involved, low uncertainty, and a comprehensive understanding derived from a broad empirical basis. If the scientific logic is used as a benchmark in the regulatory context, this may easily lead to "paralysis by analysis". While regulatory decisions should be based on sound science, discrepancies between scientific goals and regulatory needs and, consequently, different levels of requirements (must-have
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.